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Figure 3: Comorbidities & Other Factors that Drive or Inhibit NASH Nursing Implications Topic Introduction Signs & Symptoms Underlying Pathophysiology progression (Cotter & Rinella, 2020) 
• Nurses can greatly improve the 
• Nonalcoholic Fatty Liver Disease NAFLD symptoms (Mayo Clinic, 2020) health outcomes of patients with Type 2 diabetes (T2DM) and obesity are highly correlated with NAFLD and multiple factors and (NAFLD) is the presence of hepatic • Fatigue obesity, metabolic syndrome, mechanisms are thought to contribute to disease initiation and progression (Hydes et al., 2020): steatosis (fat) within the liver which is • Pain/discomfort upper right insulin resistance, and type 2 • Ectopic fat accumulation not caused by alcohol consumption, abdomen diabetes by implementing • Insulin resistance in which muscle, fat , and liver cells do not effectively respond to insulin, which virus, or medications (Sivell, 2019) • There are not many signs or appropriate and early testing or leads to poor glycemic control 
symptoms at this early stage, which imaging to determine if NAFLD or • Low adiponectin levels, which normally protect against insulin resistance and increase fatty acid • NAFLD can become  more advanced can make diagnosis difficult NASH is present. oxidation and glucose metabolism and lead to liver inflammation which is NASH & cirrhosis signs & symptoms 
• Increased inflammatory cytokines produced by dysfunctional adipose tissue diagnosed as nonalcoholic (Mayo Clinic, 2020) • Educating patients about lifestyle • Gut dysbiosis which causes intestinal permeability and activates inflammatory pathways steatohepatitis (NASH). NASH was • Abdominal swelling (ascites) and diet modifications, • Mitochondrial dysfunction first described in 1980 (Sheka et al., • Enlarged blood vessels just under the probiotic/prebiotic usage, and • These different factors cause fat to “accumulate in the liver in the form of triglycerides, leading to an 2020) epidermis medications, if appropriate, can increase in lipotoxicity because of higher levels of free fatty acids and free cholesterol causing 
• Enlarged spleen improve health outcomes-fatty mitochondrial dysfunction, oxidative stress, and the production of reactive oxygen species” (Sivell,• NASH can progress to scarring • Red palms liver can be a reversible process 2019, p.430). (cirrhosis) and liver failure, as is seen • Yellowing of eyes and skin (jaundice) 
in patients with long-term alcohol 
• Nurses should assess for 
abuse (Mayo Clinic, 2020) psychological issues that could be Diagnosis contributing to poor lifestyle 
• Risk factors for NAFLD  are obesity, choices and assist in coordinating The following tests can assist in determining dyslipidemia, type 2 diabetes mellitus support if needed (Sivell, 2019) disease severity and diagnosis (Mayo Clinic, 2020): (T2DM) and metabolic syndrome 
• Complete blood count (Sheka et al., 2020) 
• Liver enzyme and liver function tests Conclusions 
• Tests for chronic viral hepatitis 
• NAFLD is viewed as a multi-factorial • NAFLD is known as a silent disease 
• Celiac disease screening test Role of Gut Dysbiosis Treatments disease in which genome-environment and many patients do not experience 
• Fasting blood sugar interactions, diet, hormonal symptoms until advanced stages 
• Hemoglobin A1C imbalances, and gut microbiome • Weight loss, 7-10% loss of • Altered gut flora appears to increase small • Lipid profile, specifically looking at cholesterol alterations appear to play a role in the total body weight • NAFLD can be driven by a 
development and progression 
bowel permeability and causes increased fatty and triglycerides 
recommended (Hydes et al., combination of comorbidities, genetic 
(Mohammadi et al., 2020) 
acid absorption and activates inflammatory • Abdominal ultrasound (US) 
2020) factors, microbiome alterations, and cytokines, which leads to inflammation and • Computerized tomography (CT) and Magnetic 
• Exercise, average-paced lifestyle choices 
walking 3hrs/week 
steatosis in the liver  (Sivell, 2019) resonance imaging (MRI) (These cannot 
Topic Importance distinguish between NAFLD or NASH) 
substantially lowered • Advanced practice nurses should  be • It is hypothesized that metabolites produced by • Transient elastography (US that evaluates 
mortality risk (Hydes et al., knowledgeable about thorough certain gut microbiota interact with a host’s stiffness/fibrosis of liver) • “From 2004 to 2016, there was a 2020) bloodwork and imaging needed to epithelial lining and immune cells and • Magnetic resonance elastography: MRI with 114% and 80% expansion in liver 
• Pioglitazone, glucose-lowering assist in making correct and early indirectly affect the process of NAFLD (Liang et sound waves that creates an image (elastogram)transplant waitlist registration due medication (Hydes et al., 2020) diagnoses al., 2021) which shows stiffness in body to NASH for men and women, 
• Vitamin E, antioxidant that 
• Liver biopsy- *Gold standard respectively” (Sheka et al., 2020, Figure 2: Pathogenesis of NAFLD (Akshintala et al., 2019) protects against oxidative • There are no FDA approved • Lipopolysaccharides (LPS), known as 
p.1175). stress (Hydes et al., 2020) pharmaceuticals for NAFLD, but 
gram-negative bacteria, are found to be at 
endotoxins, which are found in the cell walls of 
• Avoid saturated and trans fats weight loss, exercise, pioglitazone, 
• In 2017, lifetime medical costs for 
• Avoid sugar (fructose) in diet and vitamin E have been shown to higher levels, systemically, in NAFLD patients Significance of Pathophysiology U.S. NASH patients were 
• Avoid alcohol improve NAFLD patient outcomes and have been shown to promote liver 
approximately $222 billion (Sheka 
• Synbiotics (probiotics and (Sheka et al., 2020) inflammation (Inamine & Schnabl, 2018) 
et al., 2020) prebiotics) (Inamine & 
• NAFLD, which can lead to NASH, is “now the leading indication for liver transplant listing Schnabl, 2018) • Alterations of the gut microbiome • “Probiotic treatment with Lactobacillus spp. 
• As rates of metabolic syndrome, in women and is expected to overtake alcoholic liver disease as the leading liver • Bariatric surgery (Sivell, 2019) through use of synbiotics show and Bifidobacterium spp. improved bacterial 
obesity, and T2DM rise, it is transplant indication for all patients within the next few years” These patients also “have • Liver transplant if liver failure promise in decreasing fatty acid dysbiosis and ameliorated liver injury and/or 
important for healthcare providers an increased risk of hepatocellular carcinoma” accumulation in the liver and may be inflammation in both human and animal 
to realize that NAFLD will be more (Sheka et al., 2020, p.1175). References a common therapy for treating models” (Inamine & Schnabl, 2018, p.696) 
prevalent  in patients. Healthcare • In the mid 2000’s, 20%-30% of the U.S. population met the criteria for NAFLD (Sheka et NAFLD in the future 
providers should be knowledgeable al., 2020) 
• Using this research, healthcare providers can 
about diagnosis and treatment • Approximately 3.6 million new cases of NAFLD each year (Sheka et al., 2020) 
evaluate the interaction between gut microbial 
approaches • NAFLD is a multi-system disease because it relates to increased risks of cardiovascular 
disorders, environmental factors, and diet and 
disease, chronic kidney disease, retinopathy and neuropathy related to diabetes, and 
assist a patient in developing treatment plans 
• Recent research has demonstrated extra-hepatic cancers (Hydes et al., 2020) 
to improve NAFLD progression (Liang et al., 
that gut microbiota play a pivotal • Because NAFLD has few signs and symptoms, it is important for healthcare providers to 
2021)
role in the development of NAFLD know risk factors and comorbid conditions associated with the development of the 
and the progression to NASH disease (see Figure 3) and implement appropriate testing and health recommendations 
(Yamada et al., 2017) 
Figure 1: Algorithm for diagnosis of NAFLD and 
NASH in patients with prediabetes and T2DM in 
clinical practice (Bril & Cusi, 2017) 
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